Yes, metronidazole (Flagyl) is safe to use at 36 weeks gestation.
Metronidazole can be safely administered at 36 weeks gestation, which falls within the second and third trimesters where the medication is explicitly recommended for treating bacterial vaginosis and trichomoniasis in pregnant women. 1
Evidence from Guidelines
The CDC guidelines clearly state that metronidazole is the recommended treatment for pregnant women beyond the first trimester:
For bacterial vaginosis in pregnancy: The recommended regimen is metronidazole 250 mg orally three times daily for 7 days, with alternative options including a single 2g oral dose 1
For trichomoniasis in pregnancy: After the first trimester, patients may be treated with 2g of metronidazole in a single dose 2
The 1993 CDC guidelines explicitly stated metronidazole was "contraindicated in the first trimester" but could be used "after the first trimester" 2
The 1998 CDC guidelines evolved to recommend lower doses during pregnancy to minimize fetal exposure, but continued to endorse its use in the second and third trimesters 1
FDA Drug Label Information
The FDA label for Flagyl provides important context 3:
- There are no adequate and well-controlled studies in pregnant women, but published data from case-control studies, cohort studies, and meta-analyses include more than 5,000 pregnant women who used metronidazole during pregnancy
- Most studies did not show an increased risk for congenital abnormalities or other adverse fetal outcomes following metronidazole exposure
- Reproduction studies in rats, rabbits, and mice showed no evidence of harm to the fetus
- Metronidazole crosses the placental barrier, but its effects on human fetal organogenesis are not definitively known
Research Evidence Nuances
While the guidelines support use, recent research reveals some important caveats:
Efficacy concerns: A 2021 meta-analysis found that metronidazole may not effectively reduce preterm birth risk overall, though it may be beneficial when combined with other antibiotics 4, 5
Safety profile:
- A 2021 systematic review found metronidazole was associated with a 70% increased risk of spontaneous abortion, though this should be interpreted cautiously as the severity of the underlying genitourinary infection is a major confounder 6
- The same 2021 meta-analysis found pooled odds ratio of 1.72 for spontaneous abortion and noted a significantly increased risk of congenital hydrocephaly (OR 4.06), though this requires further confirmation 4
- A 2001 prospective cohort study of 228 women (86.2% with first-trimester exposure) found no difference in major malformation rates compared to controls (1.6% vs 1.4%) 7
Clinical Algorithm for Use at 36 Weeks
At 36 weeks gestation, you are well into the third trimester, making metronidazole appropriate when indicated:
- Confirm the indication: Bacterial vaginosis, trichomoniasis, or other anaerobic infection requiring treatment
- Choose the appropriate regimen:
- Consider intravaginal alternatives: Metronidazole gel 0.75% may be used for BV if systemic side effects are a concern, though systemic therapy is often preferred 1
Important Caveats
- Avoid alcohol: Patients must discontinue alcohol or products containing propylene glycol during treatment and for at least 3 days after completion due to disulfiram-like reactions 3
- Monitor for adverse effects: Common side effects include metallic taste, headache, dizziness, and gastrointestinal disturbances 8
- Breastfeeding consideration: If delivery occurs during or shortly after treatment, metronidazole is present in breast milk at concentrations similar to maternal serum levels 3
The evidence strongly supports that at 36 weeks gestation, metronidazole is an established and guideline-recommended treatment option when clinically indicated, with decades of clinical experience demonstrating acceptable safety.